Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Rhinomed has completed a $6 million placement to institutional and sophisticated investors at $0.22 per share
  • Funds raised will be used to drive accelerated sales growth through current products, new product launches and significant store growth
  • Rhinomed develops nasal technologies such as Pronto, Turbine and Mute, to assist with breathing and sleep

Rhinomed has completed a $6 million placement to institutional and sophisticated investors at $0.22 per share.

Rhinomed is a global leader in nasal, respiratory and breathing technologies.

It has developed various products such as Pronto, Mute and Turbine, which target the sport, sleep, wellbeing and drug delivery markets.

Funds raised will be used to drive accelerated sales growth through current products, new product launches and significant store growth.

“On behalf of the Board, we are delighted with the very positive response to this capital raising. We are pleased to welcome multiple new institutional investors onto the register and appreciate the ongoing support from existing shareholders,” Chairman Ron Dewhurst said.

“The level of support speaks to the strong commercial opportunity and global potential of our proprietary platform technology and growing global distribution network,” Ron continued.

The company’s airway technologies have sought to improve the way people breathe, sleep and medicate.

Mute is a comfortable nasal dilator that’s designed to increase airflow and improve nasal breathing by gently opening the airways during sleep. It aims to prevent snoring and give people a much better sleep.

In July this year, Mute was reported as the fastest growing product in the nasal strip category in U.S. drugstores.

Rhinomed’s Turbine product is a breathing aid geared towards people playing sports or doing physical activity. It is built differently to Mute as it needs to sit comfortably in the nose while the user is moving around.

Lastly, the Pronto technologies are broken up into Pronto Sleep and Pronto Clear.

Pronto Sleep is a unique vapour inhaler that gently opens the nose and delivers a blend of four pure essential oils which help you relax and sleep better naturally.

Pronto Clear delivers six pure essential oils that help to naturally clear a stuffy, congested nose.

RNO by the numbers
More From The Market Herald
Dimerix (ASX:DXB) - Managing Director and CEO, Nina Webster

" Dimerix (ASX:DXB) expands DMX-200 study into Australia

Dimerix (DXB) has entered an agreement with the NHMRC Clinical Trials Centre at the University of Sydney to expand the CLARITY 2.

" ACCC scrambles to halt Virtus Health’s (ASX:VRT) purchase of Healius (ASX:HLS) IVF clinics

The ACCC has taken “a significant step” as it seeks an urgent injunction to stop Virtus Health’s (VRT) proposed acquisition of Adora Fertility
IDT Australia (ASX:IDT) - Chair, Alan Fisher

" IDT Australia (ASX:IDT) signs manufacturing deal with Monash University

IDT Australia (IDT) has entered a master services agreement and services order with Monash University.
Prescient Therapeutics (PTX) - CEO and MD, Steven Yatomi Clarke

" Prescient Therapeutics (ASX:PTX) to present new OmniCAR data at conference

Prescient Therapeutics (PTX) will present new results for its OmniCAR drug at the Cell & Gene Meeting on Mesa in California.